This session will provide an update for the various thrombotic and bleeding risks for the IR team. There will be a review of the various agents with pharmacology. The newer agents will be discussed, as well. The cirrhotic population will be discussed, as there has recently been a paradigm shift in the management of these patients. Finally, some cases will be presented